← 返回

IFITM1 作为预后生物标志物的整合生物信息学分析及其在前列腺腺癌中免疫学作用的研究

英文原题:Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma.

查看英文原题

Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma.

PubMed 2022/12/14(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

IFITM1 是 PRAD 患者的预后生物标志物,可作为 PRAD 潜在的免疫治疗靶点。

研究思路结论见上方概要

前列腺腺癌(PRAD)是一种高度侵袭性的恶性肿瘤,死亡率高、预后差,其潜在机制仍不清楚。我们的研究旨在利用生物信息学技术识别用于PRAD预后的新型标志物。

从GEO数据库下载GSE32571数据集,并通过limma R包分析以识别差异表达基因(DEGs)和差异表达免疫评分相关基因(DEISRGs)。通过重叠DEISRGs和DEGs进一步获得免疫相关基因(IRGs),并通过生存分析识别核心基因。此外,通过多个生物信息学数据库评估核心基因的表达水平、预后价值和潜在功能。

从GSE32571数据集中共鉴定出301个IRGs,其中IFITM1在包括PRAD在内的多种癌症中是一个下调基因。此外,IFITM1低表达与PRAD不良预后相关。GSEA表明,IFITM1相关基因的重要通路主要富集于原发性免疫缺陷、Th17细胞分化、Th1和Th2细胞分化、NK 细胞介导的细胞毒性、髓系树突状细胞活化、白细胞活化调控等。此外,IFITM1与22种肿瘤浸润免疫细胞密切相关。

展开英文摘要原文

The GSE32571 dataset was downloaded from the GEO database, and analyzed via the limma R package to identify differentially expressed genes (DEGs) and differentially expressed immune score-related genes (DEISRGs). The immune-related genes (IRGs) were further obtained by overlapping DEISRGs and DEGs, and the core gene was identified via survival analysis. Furthermore, the expression level, prognostic value, and potential functions of the core gene were evaluated via multiple bioinformatics databases.

A total of 301 IRGs were identified from the GSE32571 dataset, and IFITM1 was a down-regulated gene in several types of cancer, including PRAD. Besides, low expression of IFITM1 was associated with a poor prognosis in PRAD. GSEA indicated that the vital pathways of IFITM1-associated genes were mainly enriched in primary immunodeficiency, Th17 cell differentiation, Th1, and Th2 cell differentiation, natural killer cell-mediated cytotoxicity, myeloid dendritic cell activation, regulation of leukocyte activation, etc. Furthermore, IFITM1 was closely correlated with 22 types of tumor-infiltrating immune cells. DISCUSSION: IFITM1 was a prognostic biomarker for PRAD patients, and it can be acted as a potential immune therapy target in PRAD.

论文信息

作者
Qiao S、Zhang W、Su Y、Jiang Y
单位
Department of Urology, the Air Force 986 Hospital, Shaanxi, China.China
期刊
Frontiers in oncology2022
原文标识
PubMed 36591519 · DOI 10.3389/fonc.2022.1037535